FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling

Abstract Background Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide, but current treatment options remain limited and cause serious life-threatening side effects. Aberrant FGFR4 signaling has been validated as an oncogenic driver of HCC, and EZH2, the catalytic...

Full description

Bibliographic Details
Main Authors: Yiqi Yang, Yibo Zhang, Jieqiong Cao, Zijian Su, Fu Li, Peiguang Zhang, Bihui Zhang, Rongzhan Liu, Linhao Zhang, Junye Xie, Jingsheng Li, Jinting Zhang, Xiaojia Chen, An Hong
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-023-02659-4